Results 51 to 60 of about 4,657 (129)

Shunt surgery and lecanemab therapy in patients with idiopathic normal pressure hydrocephalus and alzheimer’s disease: a report of two cases

Acta Neurochirurgica
Idiopathic normal pressure hydrocephalus (iNPH) is a condition in the elderly commonly treated with ventriculoperitoneal (VP) or lumboperitoneal (LP) shunt surgery.
Koichi Miyazaki, Hiroya Morita, Kazunari Ishii   +2 more
doaj   +1 more source

Real-world safety profile of lecanemab: A disproportionality analysis of adverse events in the FDA adverse event reporting systemKey Points

JAPhA Pharmacotherapy
Background: Lecanemab, an antiamyloid monoclonal antibody, has emerged as a treatment option for Alzheimer disease. However, there is a pressing need for real-world evidence to inform clinical practice, particularly regarding its safety profile ...
Jayoung Han, Yuan Fang, Nicole Campbell
doaj   +1 more source

Lecanemab over a two-year duration: Key insights from a regional specialty medical center

The Journal of Prevention of Alzheimer's Disease
Background and objectives: The anti-amyloid monoclonal antibody lecanemab (Leqembi®) treats patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).
Lisa B.E. Shields, Hannah S. Hust, Gregory E. Cooper, Theresa Kluthe, Rachel N. Hart, Andrew P. Thaliath, Brandon C. Dennis, Stephanie W. Freeman, Jessica F. Cain, Whoy Y. Shang, Kendall M. Wasz, Adam T. Orr, Christopher B. Shields, Shirish S. Barve, Kenneth G. Pugh   +14 more
doaj   +1 more source

Real—world application of lecanemab in early—stage alzheimer's disease: a single—center prospective cohort analysis

Alzheimer’s Research & Therapy
Background and objectives Lecanemab (Leqembi®) has been approved for the treatment of early Alzheimer’s disease (AD) patients. However, the safety and efficacy of lecanemab in clinical practice in Asia population remain unclear.
Jia Shang, Siyan Zhong, Li Shang, Qingze Zeng, Shuai Zhao, Xiao Luo, Kaicheng Li, Xinyi Zhang, Peiyu Huang, Yaping Yan, Zhirong Liu, Baorong Zhang, Yanxing Chen   +12 more
doaj   +1 more source

Lecanemab en la enfermedad de Alzheimer

Acta Neurológica Colombiana
La hipótesis amiloide, que propone la acumulación del péptido ?-amiloide (?A) en la sinapsis, es el factor clave de la patogénesis de la enfermedad de Alzheimer (EA) y esta ha sido la idea dominante en el campo de la investigación de la EA durante casi ...
Paulina Elizabeth Bombón Albán, Johanna Vanessa Suárez Salazar, Lennyn Estuardo Albán León   +2 more
doaj   +1 more source

Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease

INNOVATIONS in Pharmacy
The Food and Drug Administration granted traditional approval of lecanemab for the treatment of Alzheimer’s disease (AD). Lecanemab is a humanized anti-amyloid monoclonal antibody directed towards Aβ protofibrils. Lecanemab is the only drug that targets
Connie Yoon, Corey Groff, Olivia Criss
doaj   +1 more source

Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data

Alzheimer’s Research & Therapy
Background Lecanemab was recently approved for the treatment of patients with early Alzheimer’s disease (AD) and demonstrated reduced senile amyloid plaque and less decline on the measures of cognition and function in clinical trials.
Moeko Noguchi-Shinohara, Takahiro Yoshinobu, Taro Ozaki, Daiki Muramatsu, Ayano Shima, Yasuhiro Sakashita, Yasutake Tada, Hiroki Yamaguchi, Junji Komatsu, Tokuhei Ikeda, Kenjiro Ono   +10 more
doaj   +1 more source

Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

The Journal of Prevention of Alzheimer's Disease
Background: Lecanemab, an antibody directed at Aβ-protofibrils and plaque, showed meaningful delay in disease progression and biological effects consistent with disease modification in the phase 3 Clarity AD trial.
Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, Marco Bozzali, Giancarlo Logroscino, Sarah Trafford, Shobha Dhadda, Michio Kanekiyo, Amanda Goodwin, Mark Hodgkinson, Steven Hersch, Michael Irizarry, Lynn Kramer, Lutz Froelich   +13 more
doaj   +1 more source

Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

Alzheimer’s Research & Therapy
Background The safety data of lecanemab in the post-marketing period has yet to be fully investigated in the current literature. We aimed to identify and characterise the safety profile of lecanemab in the post-marketing period.
Xiaoxuan Xing, Xiaotong Zhang, Ke Wang, Zhizhou Wang, Yingnan Feng, Xiaoxi Li, Yiming Hua, Lan Zhang, Xianzhe Dong   +8 more
doaj   +1 more source

Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report

Journal of Alzheimer's Disease Reports
Lecanemab is an anti-amyloid-β protofibril antibody that slows cognitive decline in early Alzheimer's disease. Although amyloid-related imaging abnormalities (ARIA) occur predominantly early in treatment, reports of hemorrhagic events during extended ...
Yugo Takahashi, Naoyuki Shiraishi, Akihiro Tsukahara, Yukari Matsuda, Takuya Nishina, Hiroo Yoshikawa, Takashi Uzu, Etsuro Mori   +7 more
doaj   +1 more source